Full history for every metric is available with a Kvantra account
Notable Labs, Ltd. (NTBL)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | ||
|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 1 | 1 | 0 | 0 | 0 |
| Operating profit | $m | -15 | |||||
| Net profit | $m | -20 | -19 | -24 | -16 | -14 | -11 |
| EPS reported | $ | -5.03 | |||||
| Operating cashflow per share | $ | -6.12 | |||||
| Capex per share | $ | 0.03 | |||||
| FCF per share | $ | -6.15 | |||||
| Free cash flow | $m | -14 | |||||
| Net debt | $m | -12 | |||||
| Book value equity | $m | 15 | |||||
| Book value per share | $ | 6.75 | |||||
| Number of shares | m | 2.24 | |||||
| DPS (TTM paid) | $ | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | ||
|---|---|---|---|---|---|---|---|
| Value | |||||||
| P/E TTM | x | - | |||||
| P/B LTM | x | 0.27 | |||||
| P/S LTM | x | 13.29 | |||||
| P/FCF LTM | x | -0.30 | |||||
| EV/EBITDA LTM | x | 0.39 | |||||
| EV/Sales LTM | x | -18.24 | |||||
| Earnings Yield LTM | % | -273.31% | |||||
| FCF Yield | % | -334.39% | |||||
| Quality | |||||||
| ROE | % | -74.53% | |||||
| ROIC | % | -84.60% | |||||
| Operating margin | % | -4728.1% | |||||
| Gross margin | % | 36.45% | |||||
| FCF/Sales | % | -4445.5% | |||||
| Growth and momentum | |||||||
| EPS Growth YoY | % | - | |||||
| Sales Growth YoY | % | +3775.0% | |||||
| Net Income Growth YoY | % | - | |||||
| FCF Growth | % | - | |||||
| Operating Profit Growth | % | - | |||||
| Dividend and capital structure | |||||||
| Dividend Yield | % | 0.00% | |||||
| Dividend Growth | % | 0.00% | |||||
| Payout Ratio | % | 0.00% | |||||
| FCF/Debt | x | -6.73 | |||||
| Net Debt/EBITDA | x | 0.68 | |||||
| EBIT/Net interest | x | 0.00 | |||||
| Net debt/market cap | % | -286.93% | |||||
| Net debt/Equity | x | -0.78 | |||||
| Gross debt/equity | x | 0.14 | |||||
Company overview
Notable Labs, Ltd. operates as a clinical-stage therapeutic platform company, concentrating on creating predictive, personalized treatments for individuals battling cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), the company virtually tests potential cancer therapies to forecast an individual patient's likely response to a specific drug. The primary goal of the PPMP is to identify and qualify patients who are expected to respond favorably before they even begin treatment, thereby significantly accelerating the clinical development process for these specific patient groups. Notable Labs' current development pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor designed to treat acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes. Additionally, it features Fosciclopirox, a prodrug of ciclopirox, also aimed at acute myeloid leukemia. The company's headquarters are located in Foster City, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Notable Labs, Ltd. (NTBL)
Notable Labs, Ltd. operates as a clinical-stage therapeutic platform company, concentrating on creating predictive, personalized treatments for individuals battling cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), the company virtually tests potential cancer therapies to forecast an individual patient's likely response to a specific drug. The primary goal of the PPMP is to identify and qualify patients who are expected to respond favorably before they even begin treatment, thereby significantly accelerating the clinical development process for these specific patient groups. Notable Labs' current development pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor designed to treat acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes. Additionally, it features Fosciclopirox, a prodrug of ciclopirox, also aimed at acute myeloid leukemia. The company's headquarters are located in Foster City, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free